NeuroSense (NRSN) Completes Safety Analysis in Alzheimer's Study, Faces Financial Challenges

NeuroSense Therapeutics (NRSN) has completed the safety evaluation for its Phase 2 study of PrimeC, targeting Alzheimer's disease. The study found PrimeC to be well-tolerated with no severe adverse effects or unforeseen safety concerns. However, the company's financial metrics indicate significant challenges, with negative earnings and cash flow figures. Market sentiment remains cautious, reflected in the stock's proximity to its 52-week low.